Geoffrey von Maltzahn, PhD
Geoffrey von Maltzahn, PhD, is a partner at Flagship Pioneering, Chief Innovation Officer and Director at Indigo and a Director at Kaleido Biosciences and Director at Sana Biotechnology.
Prior to joining Flagship, Geoffrey co-founded Sienna Biopharmaceuticals (NASDAQ: SNNA), a clinical-stage biopharmaceutical company in medical dermatology. Through his role at Flagship Pioneering, Geoffrey has co-founded Indigo Agriculture, Kaleido Biosciences, Seres Therapeutics (NASDAQ: MCRB), and Axcella Health (NASDAQ: AXLA). He recently served as Chief Executive Officer of Cobalt Biomedicine, which he led from inception to merger with Sana Biotechnology.
Geoffrey is an inventor on over 200 patent applications, and he has co-authored more than 20 peer-reviewed publications. He has received a number of awards and honors, including: Business Insider’s 30 Biotech Leaders Under 40, 2018 Boston Chamber of Commerce Ten Outstanding Young Leaders, the prestigious Lemelson-MIT Student Prize, the National Inventors Hall of Fame Graduate Student Prize, the Biomedical Engineering Society Graduate Research Award, and the Harvard-MIT Martha Gray Prize.
Geoffrey earned his PhD in biomedical engineering and medical physics from Massachusetts Institute of Technology (MIT), his M.S. in bioengineering from the University of California, San Diego and his SB in chemical engineering from MIT.